BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 18708938)

  • 1. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
    Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
    Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers.
    Sartori F; Alaggio R; Zanazzo G; Garaventa A; Di Cataldo A; Carli M; Rosolen A;
    Cancer; 2006 Apr; 106(8):1766-75. PubMed ID: 16544315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
    Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
    J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status.
    Corao DA; Biegel JA; Coffin CM; Barr FG; Wainwright LM; Ernst LM; Choi JK; Zhang PJ; Pawel BR
    Pediatr Dev Pathol; 2009; 12(4):275-83. PubMed ID: 18788887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and clinical significance of bone marrow involvement in patients with rhabdomyosarcoma.
    Krsková L; Mrhalová M; Hilská I; Sumerauer D; Drahokoupilová E; Múdry P; Kodet R
    Virchows Arch; 2010 May; 456(5):463-72. PubMed ID: 20405298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations.
    Ren YX; Finckenstein FG; Abdueva DA; Shahbazian V; Chung B; Weinberg KI; Triche TJ; Shimada H; Anderson MJ
    Cancer Res; 2008 Aug; 68(16):6587-97. PubMed ID: 18701482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens.
    Hostein I; Andraud-Fregeville M; Guillou L; Terrier-Lacombe MJ; Deminière C; Ranchère D; Lussan C; Longavenne E; Bui NB; Delattre O; Coindre JM
    Cancer; 2004 Dec; 101(12):2817-24. PubMed ID: 15536621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
    Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG
    J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma.
    Kelly KM; Womer RB; Sorensen PH; Xiong QB; Barr FG
    J Clin Oncol; 1997 May; 15(5):1831-6. PubMed ID: 9164192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.
    Parham DM; Qualman SJ; Teot L; Barr FG; Morotti R; Sorensen PH; Triche TJ; Meyer WH;
    Am J Surg Pathol; 2007 Jun; 31(6):895-901. PubMed ID: 17527077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdomyosarcoma: molecular diagnostics of patients classified by morphology and immunohistochemistry with emphasis on bone marrow and purged peripheral blood progenitor cells involvement.
    Krsková L; Mrhalová M; Sumerauer D; Kodet R
    Virchows Arch; 2006 Apr; 448(4):449-58. PubMed ID: 16365729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas.
    Davicioni E; Finckenstein FG; Shahbazian V; Buckley JD; Triche TJ; Anderson MJ
    Cancer Res; 2006 Jul; 66(14):6936-46. PubMed ID: 16849537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
    Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
    Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of PAX3-FKHR and PAX7-FKHR fusion transcripts in rhabdomyosarcoma by reverse transcriptase-polymerase chain reaction using paraffin-embedded tissue.
    Chen BF; Chen ML; Liang DC; Huang YW; Liu HC; Chen SH
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Feb; 62(2):86-91. PubMed ID: 10063718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Rudzinski ER; Teot LA; Anderson JR; Moore J; Bridge JA; Barr FG; Gastier-Foster JM; Skapek SX; Hawkins DS; Parham DM
    Am J Clin Pathol; 2013 Jul; 140(1):82-90. PubMed ID: 23765537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?
    Anderson J; Gordon T; McManus A; Mapp T; Gould S; Kelsey A; McDowell H; Pinkerton R; Shipley J; Pritchard-Jones K;
    Br J Cancer; 2001 Sep; 85(6):831-5. PubMed ID: 11556833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myogenin, AP2β, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group.
    Rudzinski ER; Anderson JR; Lyden ER; Bridge JA; Barr FG; Gastier-Foster JM; Bachmeyer K; Skapek SX; Hawkins DS; Teot LA; Parham DM
    Am J Surg Pathol; 2014 May; 38(5):654-9. PubMed ID: 24618610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.
    Folpe AL; McKenney JK; Bridge JA; Weiss SW
    Am J Surg Pathol; 2002 Sep; 26(9):1175-83. PubMed ID: 12218574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization.
    Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.